AlphAIalphai — Financial news for AI agents
investing.comJUL 73 min read$SPRY

ARS Pharmaceuticals stock falls as CEO Lowenthal steps down By Investing.com

ARS Pharmaceuticals (NASDAQ:SPRY) shares fell 5.4% in after-hours after CEO/co-founder Richard Lowenthal stepped down. President Donn Casale was appointed CEO and director effective July 7, 2026. Lowenthal ceased serving as employee/officer effective July 6. ARS commercializes neffy, an epinephrine nasal spray for Type I allergic reactions/anaphylaxis.

Original reporting
investing.com
Published Jul 7, 2026, 8:42 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 8:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$SPRY
Bearish
medium confidence
Mentioned
$SPRY
Relevance
7/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$SPRYBearishMed
01

Why it matters

A CEO transition can affect investor confidence in commercialization execution; however, the text provides no new operational metrics or guidance changes to confirm a fundamental deterioration.

02

Market read

Traders can react to the immediate after-hours selloff tied to management change and monitor for follow-through (continuity of commercialization and any new disclosures).

03

What to watch

The article doesn’t mention any change to neffy strategy, reimbursement, manufacturing, or upcoming catalysts—so the move may be more about perception than fundamentals.

Relevance 7/10Novelty 6/10Timing: after-hours Tuesday reaction to CEO succession effective July 6–7, 2026

Background

ARS Pharmaceuticals commercializes neffy (epinephrine nasal spray) for emergency treatment of Type I allergic reactions/anaphylaxis in adults and pediatric patients ≥33 lbs.

Company-level read

Ticker impact

$SPRYBearishMedium confidence
Context

ARS Pharmaceuticals shares fell 5.4% after-hours after CEO co-founder Richard Lowenthal stepped down and President Donn Casale took over July 7, 2026.

Expected impact

Near-term downside bias until investors assess continuity of the neffy commercialization plan under the new CEO.

Evidence & confidence

The article attributes the after-hours drop directly to the CEO stepping down and names the successor, but provides no new financial guidance, trial data, or regulatory/product change.

Market effects

Sector

Biopharma investors may reprice execution risk around commercialization-stage products when CEOs step down.

Regional

Limited; the catalyst is company-specific rather than a broad market driver.

Global

Low; no cross-border deal, regulator action, or supply-chain disruption is described.

Counterpoint

What could challenge this read

The board may have planned a succession path; the new CEO’s commercial track record (including scaling HEPLISAV-B) could stabilize sentiment quickly.

Key entities

  • company
    ARS Pharmaceuticals Inc

    NASDAQ-listed biopharmaceutical company commercializing neffy.

  • person
    Richard Lowenthal

    Co-founder and CEO stepping down; ceased serving as employee/officer effective July 6, 2026.

  • person
    Donn Casale

    President appointed CEO and Director effective July 7, 2026.

  • product
    neffy

    Epinephrine nasal spray indicated for emergency treatment of Type I allergic reactions, including anaphylaxis.

Read at source← All news

Related articles

JUL 15
$SPRYMed

ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO

ARS Pharmaceuticals (NASDAQ:SPRY) said CEO Richard Lowenthal will stop working for the company, effective July 6. Donn Casale, then President, was appointed CEO and Director, taking over July 7. The company also reported payer access updates for neffy, noting no new coverage decisions in the July 1 cycle and continued availability via direct coverage and a retail cash option.

yahoo.com4 min
JUL 9
$SPRYMed

What's Going on With ARS Pharma Stock Thursday? - ARS Pharmaceuticals (NASDAQ:SPRY)

ARS Pharmaceuticals (NASDAQ:SPRY) announced a leadership change. Co-founder and CEO Richard Lowenthal stepped down as employee and officer effective July 6, 2026. Donn Casale, president, was appointed CEO and director effective July 7, 2026. William Blair and analyst Lachlan Hanbury-Brown discussed a more cautious neffy outlook, lowering Q2 neffy revenue to $26.4M and fair value to $21 from $31; SPRY was down 1.6% to $7.97.

benzinga.com3 min
AUG 9
$ITWMed

Illinois Tool Works Authorizes $6 Bln Buyback

Illinois Tool Works (ITW) said its board authorized a new share repurchase program of up to $6 billion. The board also approved a 7% increase in its regular annual cash dividend to $6.88 per share, effective with the Q4 dividend of $1.72 payable Oct. 9, 2026. ITW closed at $296.66 on Friday.

rttnews.com2 min
AUG 9
$JNJMed

Money talcs: Why J&J offered $5.5bn to end cancer cases

Johnson & Johnson is offering $5.5 billion to settle most of more than 70,000 pending talc-related cancer lawsuits, according to the company. Claims allege ovarian cancer or mesothelioma linked to asbestos-contaminated talc. J&J denies wrongdoing and says cases lack merit. Prior orders include $966m (LA) and $1.5bn (Baltimore), with appeals planned.

rte.ie6 min
AUG 9
$AAPLMed

Trump Tariff Refunds Just Topped $100 Billion, and These Companies Are Receiving Some of the Largest Checks

The U.S. Supreme Court invalidated Trump IEEPA tariffs, leaving the administration to refund about $166 billion. By Aug. 4, refunds exceeded $100 billion. Apple received $2.19 billion, Amazon $600 million, and others including Walmart ($2.4B), Ford ($1.3B), GM ($500M), and Costco (~$2B) are expected to receive large checks. New Section 301 tariffs may affect prices.

yahoo.com6 min